IHI’s new funding round to include topics on CVD and arthritis
The initiative’s proposals aim to tackle current challenges in health research and innovation
Read More
Tag: osteoarthritis
Merck KGaA out-licenses osteoarthritis programme to Novartis
Potential disease modifying osteoarthritis candidate is phase II ready
Read More
New research could spot people most susceptible to infection after knee replacement surgery
Patients who are under 60 years of age, males, those with chronic pulmonary disease, diabetes, or liver disease, and people with a higher body mass index are at increased risk.
Read More
Innovate UK awards AKLRD £675,000 for osteoarthritis drug
AKL Research and Development’s early-stage osteoarthritis drug has won a prestigious award from Innovate UK, as a potential “game-changing” treatment.
Read More
Genetic study reveals possible new osteoarthritis treatment
Scientists have uncovered 52 new genetic changes linked to osteoarthritis, doubling the number of genetic regions found to be associated with the disabling condition, potentially paving the way for the development of disease-modifying therapies.
Read More
Teva, Regeneron’s fasinumab hits osteoarthritis goals
Teva and Regeneron Pharmaceuticals have unveiled positive topline results from a Phase III study assessing the safety and efficacy of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.
Read More
Anika hit by trial failure
US group Anika Therapeutics has been hit by the failure of its viscosupplement Cingal to hit targets in a Phase III trial comparing its effectiveness to a standard treatment in patients with osteoarthritis of the knee.
Read More
Liverpool Uni leads clinical trial of promising osteoarthritis drug
The University of Liverpool, in partnership with AKL Research and Development, will lead a clinical trial testing the potential of a new therapy for osteoarthritis, the most common type of arthritis in the UK that affects more than eight million people.
Read More
FDA places hold on Teva, Regeneron back pain trial
The US Food and Drug Administration has placed on hold a Phase IIb study assessing Teva and Regeneron’s investigational nerve growth factor inhibitor fasinumab for chronic low back pain.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
